Companies partner on gallium-68 imaging

2018 12 11 00 02 7009 Atom Nuclear Lab 400

ARTMS Products and Telix Pharmaceuticals have signed a partnership covering the manufacturing of a radiopharmaceutical-based imaging agent based on the gallium-68 isotope.

Calling their technology molecularly targeted radiation (MTR), the firms agreed to use the Quantm gallium-68 production system from ARTMS in the manufacture of Telix's prostate cancer imaging agent TLX591-CDx for PET imaging.

ARTMS' cyclotron technology will be used to produce high-activity gallium-68, which will then be validated for use with Telix's production process for TLX591-CDx. ARTMS also will provide Telix with technical personnel to assist with solid-target irradiation of zinc-68, and it will utilize the company's intellectual property for high-activity processing of gallium-68.

Page 1 of 435
Next Page